Interleukin-17: A new paradigm in inflammation, autoimmunity, and therapy

Journal of Periodontology

Volumn 78, Issue 6, 2007, Pages 1083-1093

  Kramer, Jill M ^a   Gaffen, Sarah L ^a,b  

^a UNIVERSITY AT BUFFALO   (United States)

^b UNIVERSITY AT BUFFALO   (United States)

Author keywords

Autoimmunity; Cytokine receptor; Inflammation; Interleukin 17; Interleukin 17 receptor; Therapeutics

Indexed keywords

INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; UNCLASSIFIED DRUG;

ANIMAL; AUTOIMMUNE DISEASE; AUTOIMMUNITY; DRUG ANTAGONISM; HUMAN; IMMUNOLOGY; INFLAMMATION; JAW DISEASE; MICROBIOLOGY; MOUSE; OSTEOLYSIS; PERIODONTAL DISEASE; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE SUBPOPULATION;

ALVEOLAR BONE LOSS; ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; INFLAMMATION; INTERLEUKIN-17; MANDIBULAR DISEASES; MAXILLARY DISEASES; MICE; OSTEOPROTEGERIN; PERIODONTAL DISEASES; RANK LIGAND; RECEPTORS, INTERLEUKIN-17; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 34147150928     PISSN: 00223492     EISSN: None     Source Type: Journal    
DOI: 10.1902/jop.2007.060392     Document Type: Review

References (118)

1. Li X, Kolltveit KM, Tronstad L, Olsen I. Systemic diseases caused by oral infection. Clin Microbiol Rev 2000;13:547-558.
2. Genco RJ. A proposed model linking inflammation to obesity, diabetes and periodontal infections. J Periodontol 2005;76(Suppl.):2075-2084.
3. Weaver CT, Harrington LE, Mangan PR, Gavrieli M, Murphy KM. Th17: An effector CD4 T cell lineage with regulatory T cell ties. Immunity 2006;24:677-688.
4. Dong C. Diversification of T-helper-cell lineages: Finding the family root of IL-17-producing cells. Nat Rev Immunol 2006;6:329-333.
5. Lubberts E, Koenders MI, van den Berg WB. The role of T cell interleukin-17 in conducting destructive arthritis: Lessons from animal models. Arthritis Res Ther 2005;7:29-37.
6. Gaffen SL. Interleukin-17: A unique inflammatory cytokine with roles in bone biology and arthritis. Arthritis Res Ther 2004;6:240-247.
7. Ozaki K, Leonard WJ. Cytokine and cytokine receptor pleiotropy and redundancy. J Biol Chem 2002; 277:29355-29358.
8. Aggarwal S, Gurney AL. IL-17: A prototype member of an emerging family. J Leukoc Biol 2002;71:1-8.
9. Kolls JK, Linden A. Interleukin-17 family members and inflammation. Immunity 2004;21:467-476.
10. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffrnan RL. Two types of murine helper T cell clones. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348-2357.
11. Gor DO, Rose NR, Greenspan NS. TH1-TH2: A procrustean paradigm. Nat Immunol 2003;4:503-505.
12. Aggarwal S, Ghilardi N, Xie MH, de Sauvage FJ, Gurney AL. Interleukin-23 promotes a distinct CD4 T cell activation state characterized by the production of interleukin-17. J Biol Chem 2003;278:1910-1914.
13. Happel KI, Zheng M, Young E, et al. Cutting edge: Roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol 2003;170:4432-4436.
14. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity 2006;24:179-189.
15. Mangan PR, Harrington LE, O'Quinn DB, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature 2006;441:231-234.
16. Bettelli E, Carrier Y, Gao W, et al. Reciprocal developmental pathways for the generation of pathogenic effector T(H)17 and regulatory T cells. Nature 2006; 441:235-238.
17. Bettelli E, Kuchroo VK. IL-12- and IL-23-induced T helper cell subsets: Birds of the same feather flock together. J Exp Med 2005;201:169-171.
18. Park H, Li Z, Yang XO, et al. A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 2005;6:1133-1141.
19. + effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nat Immunol 2005;6:1123-1132.
20. Liang SC, Tan XY, Luxenberg DP, et al. Interleukin (IL)-22 and IL-17 are coexpressed by Th17 cells and cooperatively enhance expression of antimicrobial peptides. J Exp Med 2006;203:2271-2279.
21. Cua DJ, Kastelein PA. TGF-beta, a 'double agent' in the immune pathology war. Nat Immunol 2006;7:557-559.
22. + T-cell clones derived from gingival tissues of periodontitis patients. Oral Microbiol Immunol 2005;20:382-386.
23. Takahashi K, Azuma T, Motohira H, Kinane DF, Kitetsu S. The potential role of interleukin-17 in the immunopathology of periodontal disease. J Clin Periodontol 2005;32:369-374.
24. Vernal R, Dutzan N, Chaparro A, Puente J, Antonieta Valenzuela M, Gamonal J. Levels of interleukin-17 in gingival crevicular fluid and in supematants of cellular cultures of gingival tissue from patients with chronic periodontitis. J Clin Periodontol 2005;32:383-389.
25. Oda T, Yoshie H, Yamazaki K. Porphyromonas gingivalis antigen preferentially stimulates T cells to express IL-17 but not receptor activator of NF-kappaB ligand in vitro. Oral Microbiol Immunol 2003;18:30-36.
26. Fossiez F, Djossou O, Chomarat P, et al. T cell interleukin-17 induces stromal cells to produce proinflammatory and hematopoietic cytokines. J Exp Med 1996;183:2593-2603.
27. Yao Z, Painter SL, Fanslow WC, et al. Cutting edge: Human IL-17: A novel cytokine derived from T cells. J Immunol 1995;155:5483-5486.
28. Stark MA, Huo Y, Burcin TL, Morris MA, Olson TS, Ley K. Phagocytosis of apoptotic neutrophils regulates granulopoiesis via IL-23 and IL-17. Immunity 2005;22:285-294.
29. Lockhart E, Green AM, Flynn J. IL-17 production by gammadelta T cells rather than CD4 T cells during Mycobacterium tuberculosis infection. J Immunol 2006;177:4662-4669.
30. Ruddy MJ, Shen F, Smith J, Sharma A, Gaffen SL. Interleukin-17 regulates expression of the CXC chemokine LIX/CXCL5 in osteoblasts: Implications for inflammation and neutrophil recruitment. J Leukoc Biol 2004;76:135-144.
31. Shen F, Ruddy MJ, Plamondon P, Gaffen SL. Cytokines link osteoblasts and inflammation: Microarray analysis of interleukin-17- and TNF-alpha-induced genes in bone cells. J Leukoc Biol 2005;77:388-399.
32. Yao Z, Fanslow WC, Seldin MF, et al. Herpesvirus saimiri encodes a new cytokine, IL-17, which binds to a novel cytokine receptor. Immunity 1995;3:811-821.
33. Ye P, Rodriguez FH, Kanaly S, et al. Requirement of interleukin 17 receptor signaling for lung CXC chemokine and granulocyte colony-stimulating factor expression, neutrophil recruitment, and host defense. J Exp Med 2001;194:519-527.
34. Baker P. The role of immune responses in bone loss during periodontal disease. Microbes Infect 2000;2:1181-1192.
35. Taubman MA, Valverde P, Han X, Kawai T. Immune response: The key to bone resorption in periodontal disease. J Periodontol 2005; 76:2033-2041.
36. Theill L, Boyle W, Penninger J. PANK-L and RANK: T cells, bone loss and mammalian evolution. Annu Rev Immunol 2002;20:795-823.
37. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-1352.
38. Teitelbaum SL, Ross FP. Genetic regulation of osteoclast development and function. Nat Rev Genet 2003; 4:638-649.
39. Roodman GD. Regulation of osteoclast differentiation. Ann N Y Acad Sci 2006;1068:100-109.
40. Kawai T, Matsuyama T, Hosokawa Y, et al. B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am J Pathol 2006;169:987-998.
41. Wada T, Nakashima T, Hiroshi N, Penninger JM. PANKL-RANK signaling in osteoclastogenesis and bone disease. Trends Mol Med 2006;12:17-25.
42. Lubberts E, van den Bersselaar L, Oppers-Walgreen B, et al. IL-17 promotes bone erosion in murine collagen-induced arthritis through loss of the receptor activator of NF-kappa B ligand/osteoprotegerin balance. J Immunol 2003;170:2655-2662.
43. Nakashima T, Kobayashi Y, Yamasaki S, et al. Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: Modulation of the expression by osteotropic factors and cytokines. Biochem Biophys Res Commun 2000;275:768-775.
44. Van Bezooijen RL, Farih-Sips HCM, Papapoulos SE, Löwik CWGM. Interleukin-17: A new bone acting cytokine in vitro. J Bone Miner Res 1999;14:1513-1521.
45. Van Bezooijen RL, Papapoulos SE, Lowik CW. Effect of interleukin-17 on nitric oxide production and osteoclastic bone resorption: Is there dependency on nuclear factor-kappaB and receptor activator of nuclear factor kappaB (RANK)/PANK ligand signaling? Bone 2001;28:378-386.
46. Sato K, Suematsu A, Okamoto K, et al. Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med 2006;203:2673-2682.
47. Scannapieco FA, Genco RJ. Association of periodontal infections with atherosclerotic and pulmonary diseases. J Periodontal Res 1999;34:340-345.
48. Offenbacher S. Maternal periodontal infections, prematurity, and growth restriction. Clin Obstet Gynecol 2004;47:808-821.
49. D'Aiuto F, Parkar M, Nibali L, Suvan J, Lessem J, Tonetti MS. Periodontal infections cause changes in traditional and novel cardiovascular risk factors: Results from a randomized controlled clinical trial. Am Heart J 2006;151:977-984.
50. Mercado FB, Marshall RI, Bartold PM. Inter-relationships between rheumatoid arthritis and periodontal disease. A review. J Clin Periodontol 2003;30:761-772.
51. Genco R, Offenbacher S, Beck J. Periodontal disease and cardiovascular disease: Epidemiology and possible mechanisms. J Am Dent Assoc 2002;133(Suppl.): 14S-22S.
52. D'Aiuto F, Ready D, Tonetti MS. Periodontal disease and C-reactive protein-associated cardiovascular risk. J Periodontal Res 2004;39:236-241.
53. Ioannidou E, Malekzadeh T, Dongari-Bagtzoglou A. Effect of periodontal treatment on serum C-reactive protein levels: A systematic review and meta-analysis. J Periodontol 2006;77:1635-1642.
54. Lubberts E. The role of IL-17 and family members in the pathogenesis of arthritis. Curr Opin Investig Drugs 2003;4:572-577.
55. Nakae S, Saijo S, Horai R, Sudo K, Mori S, Iwakura Y. IL-17 production from activated T cells is required for the spontaneous development of destructive arthritis in mice deficient in IL-1 receptor antagonist. Proc Natl Acad Sci USA 2003;100:5986-5990.
56. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic T cell population that induces autoimmune inflammation. J Exp Med 2005;201:233-240.
57. Komiyama Y, Nakae S, Matsuki T, et al. IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J Immunol 2006; 177:566-573.
58. Matusevicius D, Kivisakk P, He B, et al. Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 1999; 5:101-104.
59. Kotake S, Udagawa N, Takahashi N, et al. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 1999;103:1345-1352.
60. Teunissen MB, Koomen CW, de Waal Malefyt R, Wierenga EA, Bos JD. Interleukin-17 and interferon-g synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998;111:645-649.
61. Zhang Z, Zheng M, Bindas J, Schwarzenberger P, Kolls JK. Critical role of IL-17 receptor signaling in acute TNBS-induced colitis. Inflamm Bowel Dis 2006;12:382-388.
62. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science 2006;314:1461-1463.
63. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis 2004; 190:624-631.
64. Kelly MN, Kolls JK, Happel K, et al. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect Immun 2005;73:617-621.
65. Yu JJ, Ruddy M J, Wong GC, et al., An essential role for IL-17 in preventing pathogen-initiated bone destruction: Recruitment of neutrophils to inflamed bone requires IL-17 receptor-dependent signals. Blood 2007;109:3794-3802.
66. Rutitzky LI, Lopes da Rosa JR, Stadecker MJ. Severe CD4 T cell-mediated immunopathology in murine schistosomiasis is dependent on IL-12p40 and correlates with high levels of IL-17. J Immunol 2005;175: 3920-3926.
67. Moseley TA, Haudenschild DR, Rose L, Reddi AH. Interleukin-17 family and IL-17 receptors. Cytokine Growth Factor Rev 2003;14:155-174.
68. Hymowitz SG, Filvaroff EH, Yin JP, et al. IL-17s adopt a cystine knot fold: Structure and activity of a novel cytokine, IL-17F, and implications for receptor binding. EMBO J 2001;20:5332-5341.
69. Hizawa N, Kawaguchi M, Huang SK, Nishimura M. Role of interleukin-17F in chronic inflammatory and allergic lung disease. Clin Exp Allergy 2006;36:1109-1114.
70. McAllister F, Henry A, Kreindler JL, et al. Role of IL-17A, IL-17F, and the IL-17 receptor in regulating growth-related oncogene-alpha and granulocyte colony-stimulating factor in bronchial epithelium: Implications for airway inflammation in cystic fibrosis. J Immunol 2005;175:404-412.
71. Kramer J, Yi L, Shen F, et al. Cutting edge: Evidence for ligand-independent multimerization of the IL-17 receptor. J Immunol 2006;176:711-715.
72. Toy D, Kugler D, Wolfson M, et al. Cutting edge: Interleukin-17 signals through a heteromeric receptor complex. J Immunol 2006;177:36-39.
73. Haudenschild D, Moseley T, Rose L, Reddi AH. Soluble and transmembrane isoforms of novel interleukin-17 receptor-like protein by RNA splicing and expression in prostate cancer. J Biol Chem 2002;277: 4309-4316.
74. Haudenschild DR, Curtiss SB, Moseley TA, Reddi AH. Generation of interleukin-17 receptor-like protein (IL-17RL) in prostate by alternative splicing of RNA. Prostate 2006;66:1268-1274.
75. Romagnani S. Th1 and Th2 in human diseases. Clin Immunol Immunopathol 1996;80:225-235.
76. Burns F, Marrack P, Kappler J, Janeway C: Functional heterogeneity among the T-derived lymphocytes of the mouse. IV. Nature of spontaneously induced suppressor cells. J Immunol 1975;114:1345-1347.
77. Taams LS, Palmer DB, Akbar AN, Robinson DS, Brown Z, Hawrylowicz CM. Regulatory T cells in human disease and their potential for therapeutic manipulation. Immunology 2006;118:1-9.
78. Frey O, Brauer R. Regulatory T cells: Magic bullets for immunotherapy? Arch Immunol Ther Exp (Warsz) 2006;54:33-43.
79. Lutton JD, Winston R, Rodman TC. Multiple sclerosis: Etiological mechanisms and future directions. Exp Biol Med (Maywood) 2004;229:12-20.
80. Morgan ME, Sutmuller RP, Witteveen HJ, et al. CD25+ cell depletion hastens the onset of severe disease in collagen-induced arthritis. Arthritis Rheum 2003;48: 1452-1460.
81. Mottet C, Uhlig HH, Powrie F. Cutting edge: Cure of colitis by CD4+CD25+ regulatory T cells. J Immunol 2003;170:3939-3943.
82. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949.
83. Cao D, van Vollenhoven R, Klareskog L, Trollmo C, Malmstrom V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004;6:R335-R346.
84. Ehrenstein MR, Evans JG, Singh A, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFalpha therapy. J Exp Med 2004;200:277-285.
85. Viglietta V, Baecher-Allan C, Weiner HL, Hafler DA. Loss of functional suppression by CD4+CD25+ regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199:971-979.
86. Gemmell E, Winning TA, Carter CL, et al. Differences in mouse strain influence leukocyte and immunoglobulin phenotype response to Porphyromonas gingivalis. Oral Microbiol Immunol 2003;18:364-370.
87. Kawai T, Eisen-Lev R, Seki M, Eastcott JW, Wilson ME, Taubman MA. Requirement of B7 costimulation for Th1-mediated inflammatory bone resorption in experimental periodontal disease. J Immunol 2000; 164:2102-2109.
88. Taubman MA, Kawai T. Involvement of T-lymphocytes in periodontal disease and in direct and indirect induction of bone resorption. Crit Rev Oral Biol Med 2001;12:125-135.
89. Teng YT. The role of acquired immunity and periodontal disease progression. Crit Rev Oral Biol Med 2003;14:237-252.
90. Yamashita K, Eastcott JW, Taubman MA, Smith DJ, Cox DS. Effect of adoptive transfer of cloned Actinobacillus actinomycetemcomitans-specific T helper cells on periodontal disease. Infect Immun 1991;59:1529-1534.
91. Yamazaki K, Yoshie H, Seymour GJ. T cell regulation of the immune response to infection in periodontal diseases. Histol Histopathol 2003;18:889-896.
92. Seymour GJ, Gemmell E. Cytokines in periodontal disease: Where to from here? Acta Odontol Scand 2001;59:167-173.
93. Johnson RB, Wood N, Serio FG. Interleukin-11 and IL-17 and the pathogenesis of periodontal disease. J Periodontol 2004;75:37-43.
94. Lopez NJ, Jara L, Valenzuela CY. Association of interleukin-1 polymorphisms with periodontal disease. J Periodontol 2005;76:234-243.
95. Moreira PR, de Sa AR, Xavier GM, et al. A functional interleukin-1 beta gene polymorphism is associated with chronic periodontitis in a sample of Brazilian individuals. J Periodontal Res 2005;40:306-311.
96. Lin S J, Chen YL, Kuo MY, Li CL, Lu HK. Measurement of gp130 cytokines oncostatin M and IL-6 in gingival crevicular fluid of patients with chronic periodontitis. Cytokine 2005;30:160-167.
97. Baker PJ, Dixon M, Evans RT, Dufour L, Johnson E, Roopenian DC. CD4(+) T cells and the proinflammatory cytokines gamma interferon and interleukin-6 contribute to alveolar bone loss in mice. Infect Immun 1999;67:2804-2809.
98. Kikuchi T, Willis DL, Liu M, et al. Dendritic-NK cell interactions in P. gingivalis-specific responses. J Dent Res 2005; 84:858-862.
99. Ruddy M J, Wong GC, Liu XK, et al. Functional cooperation between interleukin-17 and tumor necrosis factor-a is mediated by CCAAT/enhancer binding protein family members. J Biol Chem 2004; 279:2559-2567.
100. Shen F, Hu Z, Goswami J, Gaffen SL. Identification of common transcriptional regulatory elements in interleukin-17 target genes. J Biol Chem 2006;281:24138-24148.
101. Linden A, Laan M, Anderson G. Neutrophils, interleukin-17A and lung disease. Eur Respir J 2005;25: 159-172.
102. Chung KF. Cytokines as targets in chronic obstructive pulmonary disease. Curr Drug Targets 2006;7:675-681.
103. Hashmi S, Zeng QT. Role of interleukin-17 and interleukin-17-induced cytokines interleukin-6 and interleukin-8 in unstable coronary artery disease. Coron Artery Dis 2006;17:699-706.
104. von der Thusen JH, Kuiper J, van Berkel TJ, Biessen EA. Interleukins in atherosclerosis: Molecular pathways and therapeutic potential. Pharmacol Rev 2003; 55:133-166.
105. Miljkovic D, Cvetkovic 1, Momcilovic M, Maksimovic-Ivanic D, Stosic-Grujicic S, Trajkovic V. Intedeukin-17 stimulates inducible nitric oxide synthase-dependent toxicity in mouse beta cells. Cell Mol Life Sci 2005; 62:2658-2668.
106. Vukkadapu SS, Belli JM, Ishii K, et al. Dynamic interaction between T cell-mediated beta-cell damage and beta-cell repair in the run up to autoimmune diabetes of the NOD mouse. Physiol Genomics 2005; 21:201-211.
107. Kikly K, Liu L, Na S, Sedgwick JD. The IL-23/Th(17) axis: Therapeutic targets for autoimmune inflammation. Curr Opin Immunol 2006;18:670-675.
108. Amin AR. Type II interleukin-1beta receptor: A candidate for gene therapy in human arthritis. Clin Orthop 2000; 379(Suppl.):S179-S188.
109. Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: Radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum 2000;43:1001-1009.
110. Bendele AM, Chlipala ES, Scherrer J, et al. Combination benefit of treatment with the cytokine inhibitors interleukin-1 receptor antagonist and PEGylated soluble tumor necrosis factor receptor type I in animal models of rheumatoid arthritis. Arthritis Rheum 2000; 43:2648-2659.
111. Hyrich KL, Watson KD, Silman AJ, Symmons DP. Predictors of response to anti-TNF-{alpha} therapy among patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 2006;45:1558-1565.
112. Heldin C-H. Dimerization of cell surface receptors in signal transduction. Cell 1995;80:213-223.
113. Kishimoto T, Taga T, Akira S. Cytokine signal transduction. Cell 1994;76:253-262.
114. Weiss A, Schlessinger J. Switching signals on or off by receptor dimerization. Cell 1998;94:277-280.
115. Chan FK, Chun HJ, Zheng L, Siegel RM, Bui KL, Lenardo MJ. A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science 2000;288:2351-2354.
116. Siegel PM, Frederiksen JK, Zacharias DA, et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 2000;288:2354-2357.
117. Chan FK-M. The pre-ligand binding assembly domain: A potential target of inhibition of tumour necrosis factor receptor function. Ann Rheum Dis 2000; 59(Suppl. I):i50-i53.
118. Deng GM, Zheng L, Chan FK, Lenardo M. Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors. Nat Med 2005;11:1066-1072.